We are busy preparing for the first United Nations General Assembly MASH side-event, 23 Sept 2024 - in NYC. We need a whole-of-society effort to end this public health threat. For ex food inequity + insecurity are MASLD and MASH risk factors: nature.com/articles/s4157… #LiverTwitter

Must read paper on azathioprine dosing in autoimmune hepatitis in HEPATOLOGY Journal This summary figure is gold 1. TGN target 2. When to add allopurinol

Hatef Massoumi, MD Juan Pablo (JP) Arab, MD  In CAMARO, there was effectively equivalence in the ITT populations and the astronomical drop out rate (26%) in aza is wildly discordant with the patients we see in clinic with huge (30%) rates of nausea and vomiting

In people with metabolic syndrome, drinking moderate amounts of alcohol does not only favor advanced liver disease, but also increases CANCER-RELATED MORTALITY. Close cancer surveillance is recommended in this population. t.ly/O42u0 Juan Pablo (JP) Arab, MD  Mazen Noureddin, MD, MHSc

To learn more about the use of blood-based NILDA in CLD, Medscape spoke with lead author Richard Sterling --our chief medical officer -- on the AASLD practice guidelines on imaging-based and blood-based NILDA guidelines. #livertwitter wb.md/3T65LNV

Agradezco este reconocimiento que me hace el Congreso de la República por la trayectoria médica y apoyo a la Comunidad que refleja el trabajo que venimos haciendo con todo el equipo de médicos , enfermeras y técnicas del Servicio de Gastro y Hepatología del Hospital Loayza 🇵🇪

¿Sos miembro de ALEH ? ¿Vas a asistir al congreso #ALEH2024? ¡Entonces no te podes perder el taller de #IA! El gran Juan Turnes nos enseñará como podemos utilizar la #IA para mejorar nuestra productividad científica. Inscripciones 👉 [email protected]

Big thank you to FattyLiverAlliance for doing this virtual tour of our brand new phase 1 unit. Our team is ready to do cutting edge trials including hepatic impairment/ Renal impairment/ first in human/ DDI/ food impact/ SAD/ MAD/ and mechanistic studies. Elliot Tapper Mazen Noureddin, MD, MHSc

Introducing the 2024 Ashwani K. Singal Advanced/Transplant Hepatology Fellow Awardee! 🤩 Huge congrats to Hanna Blaney, MD, MPH. Learn more about AASLD Foundation's 2024 awardees at aasldfoundation.org/2024-research-…

"Best buy interventions to address the burden of steatotic liver disease". Out Today in the The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa… Join the discussion at the first United Nations General Assembly MASH side-event, 23 Sept 2024 in NYC: events.economist.com/custom-events/… #LiverTwitter

At Paris MASH Meeting, hepatologists from our institute are sharing knowledge garnered from the latest liver research and best practices on bringing the best treatments to #MASH and #MASLD patients. #livertwitter paris-mash.org for more details. Arun J. Sanyal Saul Karpen

✈️ Últimos retoques antes de despegar hacia Santiago de Chile! Emocionado de poder participar en el Congreso de ALEH dando un taller práctico sobre #IA generativa en medicina 🔥 📅 congresoaleh.com

#ALEH2024 Brett E Fortune MD ✅Shifting paradigm NSBB to prevent not only variceal🩸 but also liver decomp ✅Assessing PHT in obese MASH pts is still limited ✅Still waiting for novel biomarkers to detect fibrosis/CSPH ALEH

Our fellows enjoying time together in Williamsburg. #WereNo11

Infecciones en cirrosis #ALEH2024 Sebastian Marciano ✅La vigilancia epidemiólogica es clave para escoger ATB empírico ✅ multiresistencia 70% en ITU nosocomial ✅considerar Insuf Suprarrenal en shock séptico 👉Registro de infecciones en cirrosis activo. Interesados contactarlo

Opening the post-grad course at #ALEH2024. Fantastic to be back in Santiago, Chile, after 33 years. Here are 2 of the papers I referred to: journals.lww.com/hep/fulltext/2… journal-of-hepatology.eu/article/S0168-… #LiverTwitter

📢 Ahora #ALEH2024 📍Santiago, Chile Taller de #AI Manuel Mendizabal generalidades de la #AI ALEH Juan Turnes

My privilege to talk at this meeting in this beautiful city AASLD Marco Arrese, MD

Bret Fortune in Chile: using elastography to avoid screening endoscopy in cirrhosis. Cost effective! If the liver stiffness is less than 15kpa, no endoscopy If more than 25, carvedilol